SESSION 6: CLINICAL TRIALS – PROMISE AND CONSIDERATIONS

1:00 p.m.
Introduction and Panel Chairs
Shalini Padmanabhan, Ph.D. – The Michael J. Fox Foundation
Roy N. Alcalay, M.D., M.S. – Columbia University

Group A: LRRK2 Therapeutics

1:05 p.m.       Joseph Lewcock, Ph.D. – Denali (DNL-201/DNL-151)

1:15 p.m.       Warren Hirst, Ph.D. – Ionis/Biogen (BIIB094)

1:25 p.m.       Matthew Fell, Ph.D. – Merck (inhibitors)

1:35 p.m.       Alastair Reith, Ph.D. – GlaxoSmithKline Pharmaceuticals (inhibitors)

Group B: GBA Therapeutics

1:45 p.m.      Olga Uspenskaya, M.D., Ph.D. – Prevail Therapeutics

1:55 p.m.       S. Pablo Sardi, Ph.D. – Genzyme/Sanofi (Venglustat)

2:05 p.m.       Anthony Schapira, MD, DSc, FRCP, FMedSci – UCL (Ambroxol)

2:15 p.m.       Peter Lansbury, Ph.D. Lysosomal Therapeutics – Bial Biotech (LTI/Bial)

2:25 p.m.      
Panel discussion